Br J Dermatol:局部光动力疗法治疗浅表性基底细胞癌时,是否应该采取二步光照法?

2017-09-30 xiaoxiao MedSci原创

基底细胞癌(Basal cell carcinoma,BCC)是最常见的皮肤癌类型,其发病率明显呈上升趋势。光动力疗法(PDT)是一种常用的治疗BCC的方法,尤其针对浅表性BCC(SBCC)。目前有两种表面光敏化剂用于治疗SBCC:5-氨基乙酰丙酸(ALA)及其甲酯(MAL)。以往的研究表明,使用二步法光照的ALA-PDT疗法有更好的疗效,二步法光照指在应用ALA后的4小时和6小时时,分别的光照剂

背景:基底细胞癌(Basal cell carcinoma,BCC)是最常见的皮肤癌类型,其发病率明显呈上升趋势。光动力疗法(PDT)是一种常用的治疗BCC的方法,尤其针对浅表性BCC(SBCC)。目前有两种表面光敏化剂用于治疗SBCC:5-氨基乙酰丙酸(ALA)及其甲酯(MAL)。以往的研究表明,使用二步法光照的ALA-PDT疗法有更好的疗效,二步法光照指在应用ALA后的4小时和6小时时,分别的光照剂量为20 J/cm2和80J/cm2。

方法:研究人员在荷兰进行了一项单盲、随机对照、多中心临床试验。

结果:研究共纳入了162例患者,随机分配接受常规MAL-PDT或ALA-PDT二步光照法。12个月后,ALA-PDT组共有6例治疗失败后,而MAL-PDT组有13例;治疗未失败的12个月的累积概率分别为92.3%(95% CI [ 83.7-96.5 ])和83.4(95% CI [ 73.1-90.0 ])(P = 0.091)。

结论:ALA-PDT的二步光照法方案减少了复发,但治疗组之间的差异无统计学意义。相反,与MAL-PDT组相比,它导致了疼痛和治疗后的副作用。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]
    2017-10-09 虈亣靌

    最后一点解读亮了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]
    2017-10-02 chg122
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]
    2017-10-02 仁医06
  6. [GetPortalCommentsPageByObjectIdResponse(id=1994077, encodeId=77bf19940e7fd, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 09 16:55:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978580, encodeId=974c19e8580eb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Jan 25 23:55:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251624, encodeId=feaa251624a2, content=最后一点解读亮了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Oct 09 23:11:19 CST 2017, time=2017-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405758, encodeId=7b6e1405e5880, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508954, encodeId=eea6150895442, content=<a href='/topic/show?id=0bc628824a4' target=_blank style='color:#2F92EE;'>#光照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28824, encryptionId=0bc628824a4, topicName=光照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546294, encodeId=493b154629463, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Oct 02 14:55:00 CST 2017, time=2017-10-02, status=1, ipAttribution=)]

相关资讯

BMJ:带蒂鼻结节-案例报道

该患者选择接受莫氏手术,并在随后进行鼻翼重建,随访三个月后,患者美容效果较好,没有复发的证据。

BMJ:TNF抑制剂可能降低类风湿性关节炎患者的鳞状细胞癌和基底细胞癌风险

该研究的目的是探讨未经生物药物治疗的类风湿性关节炎患者,开始使用肿瘤坏死因子(TNF)抑制剂治疗的患者,以及普通人群患鳞状细胞和基底细胞皮肤癌的风险。原始出处:Pauline Raaschou,Julia F Simard,Charlotte Asker Hagelberg,et al.Rheumatoid arthritis, anti-tumour necrosis factor treatm

NEJM:口服烟酰胺(VB3)可降低皮肤癌风险

非黑色素瘤皮肤癌如基底细胞癌、鳞状细胞癌,通常是由紫外线(UV)辐射导致的。而有研究表明烟酰胺(VB3)可以对UV造成的损伤产生拮抗保护作用,并且减少新的光化性角化病(癌前病变)。 研究者进行了一项双盲、随机、对照的3期试验,研究对象需满足以下条件:纳入研究前5年至少2种非黑色素瘤皮肤癌。研究者按1:1比例将386名研究对象分为2组,一组服用烟酰胺500mg ,每日两次;另一组则服用安慰剂,服药时

JCO:口服抗真菌药伊曲康唑可治疗基底细胞癌

目前美国食品和药品管理局(FDA)已经批准了一些药物用来治疗基底细胞癌(BCC),如vismodegib、咪喹莫特、氟尿嘧啶等。其中vismodegib通过抑制Hedgehog信号转导通路达到治疗BCC的目的,但常会出现一些不良反应如脱发、体重减轻、肌肉痉挛等,这使得该药不能作为大多数非进展期BCC的一种可行的治疗选择;另外,咪喹莫特和氟尿嘧啶这样的局部化疗药仅仅对占所有BCC类型的30%的浅表型

JCO:绝经后使用激素治疗导致基底细胞癌风险增加

基底细胞癌(BCC)作为人类最常见的恶性肿瘤,紫外线照射是其首要病因之一。过去几年的研究证实雌激素具有光敏化特征,但是关于生殖因素或外源性雌激素使用与BCC的研究却没有。因此研究者进行了一项大型的、国际的、前瞻性队列研究,评估生殖因素、外源性雌激素使用和原发BCC首次发生的风险间关系。研究结果发现,绝经年龄较晚的人群BCC风险更高 :≥55岁 vs 50-54岁 HR=1.50; 95% CI,

J Am Acad Dermatol:Vismodegib治疗皮肤基底细胞癌,并不会增加鳞状细胞癌风险

Vismodegib是治疗局部晚期基底细胞癌(basal cell carcinoma,BCC)和转移性BCC的一种靶向Hedgehog信号通路的首创新药。但在使用这种药物治疗的患者中继发性的鳞状细胞癌的风险还未确定。因此,来自美国的研究人员设计并完成了该研究,旨在确定vismodegib治疗是否与皮肤鳞状细胞癌的风险增加有关,他们将研究结果发表在了最新一期的上。